Fact checks · Stem cells and clinics
“Can an offshore stem cell clinic repair my nerves or rebuild my immune system with MSC infusions?”
The bottom line
Commercial mesenchymal stromal cell infusions are not supported as an effective MS treatment, and unapproved products can expose people to serious harm and substantial expense.
Why people are talking about it
Clinics market mesenchymal stem or stromal cells (MSCs) using claims about immune regulation and tissue repair. Patient testimonials and the broad label "stem cells" can make these offerings sound equivalent to specialist aHSCT, although they are different procedures.
What the research says
Uccelli and colleagues' MESEMS trial was a multicentre, randomized, double-blind, placebo-controlled crossover phase 2 study involving 144 people with active MS. Participants received an intravenous infusion of their own bone-marrow-derived MSCs or placebo, then crossed over at week 24. MSC treatment did not significantly reduce the primary efficacy outcome, gadolinium-enhancing MRI lesions over the first 24 weeks. Infusions were generally well tolerated within this controlled study, but that does not establish long-term safety or effectiveness for commercial products. These findings do not demonstrate nerve repair or justify substituting MSCs for established MS treatment. The FDA states that regenerative medicine therapies have not been approved to treat MS and warns that trial registration alone does not establish approval or lawful marketing.
What we don't know yet
Different cell sources, manufacturing methods, doses and administration routes cannot be treated as interchangeable. Whether a particular rigorously manufactured MSC product can deliver a meaningful, durable clinical benefit remains a research question, not a reason to purchase an unproven infusion.
Risks and costs
The FDA has received reports of infections, unwanted immune reactions, tumour formation and other serious harms across unapproved regenerative medicine products, although these reports are not all specific to intravenous MSC treatment for MS. Poorly characterized products and inadequate follow-up add uncertainty beyond the risks measured in regulated trials. Private treatment, repeat infusions, travel and treatment of complications can create substantial out-of-pocket costs without proven benefit. Stopping or delaying a proven DMT to pursue an unsupported clinic can leave MS activity insufficiently treated.
Questions to bring to your neurologist
- What controlled evidence supports this exact cell product, dose and route for my form of MS?
- Can you independently verify the regulator's authorization, manufacturing safeguards and adverse-event arrangements?
- Is there a legitimate research trial I could join without abandoning appropriate MS treatment?
Sources
- Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial (RCT, 2021)
- MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis (Report, 2019)
- Important Patient and Consumer Information About Regenerative Medicine Therapies (Regulatory, 2021)
This is information, not medical advice. Talk to your neurologist before changing anything.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error